secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001213900-26-051727
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech secures additional $607,200 convertible loan from AlpineBrook; consideration shares increased to 12.0M
--------------------------------------------------------------------------------

- Additional loan of $607,200 (net $552,000 after $55,200 facilitation fee) from AlpineBrook Capital.
- New convertible note (Additional Note #1) bears interest at the Applicable Rate, converts at $0.08 per share.
- Consideration shares increased to 12,009,780, issuable in five installments over 25 months.
- Additional warrant issued to AlpineBrook for up to 3x principal/conversion price shares, exercise price $0.08, ten-year term.
- Voting agreement requires shareholders to authorize sufficient common stock for conversion and exercise of warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/0001213900-26-051727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/ea0288796-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-051727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer